Drug Database
CL

clomiphene citrate (Omifin / Clomid)

✓ Approved

Sanofi S.A · 小分子 · 小分子

什么是 clomiphene citrate?

clomiphene citrate 是一种小分子,由Sanofi S.A研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Omifin, Clomid
公司Sanofi S.A
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

clomiphene citrate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersInfertility female✓ Approved

相关研究文献

PubMedCancer & metabolism2026-11-19

Salidroside decreases lipid abundance, mitochondrial function, and expression of the mitochondrial citrate transporter SLC25A1 via miR-1343-3p in gastric cancer.

Cao Mingyuan M, Zhang Zhendong Z, Du Yuxin Y, Fang Jin J et al.

To investigate the potential mechanisms by which salidroside regulates mitochondrial function, SLC25A1 expression, and lipid abundance in gastric cancer (GC) cells via miR-1343-3p. Transcriptome sequencing was performed on MGC-803 cells before and after salidroside treatment to identify differentially expressed miRNAs and mRNAs. Bioinformatic analysis was then used to screen for candidate molecules. The interaction between miR-1343-3p and SLC25A1 was validated by dual-luciferase reporter assay, sequence alignment, and RNA immunoprecipitation (RIP). Mitochondrial morphology and function were examined by transmission electron microscopy and fluorescent probes. MGC-803 and AGS cells were used to assess the effects of salidroside, miR-1343-3p modulation, and SLC25A1 silencing on mitochondrial citrate export, lipid abundance, and cell proliferation. Furthermore, a nude mouse xenograft model was established to evaluate the effects of salidroside and a miR-1343-3p agomir on tumor growth, the expression of miR-1343-3p and SLC25A1, and tumor metabolic status. Transcriptome sequencing revealed 44 differentially expressed miRNAs and 1,384 differentially expressed mRNAs in MGC-803 cells following salidroside treatment. Among them, miR-1343-3p was significantly upregulated as a tumor-suppressive miRNA, while SLC25A1, a mitochondrial citrate transporter, was significantly downregulated. RT-qPCR and Western blot results demonstrated that salidroside significantly increased the expression of miR-1343-3p while decreasing the mRNA and protein expression of SLC25A1. Dual-luciferase reporter, sequence alignment, and RIP assays confirmed that miR-1343-3p directly targets SLC25A1. Further studies showed that salidroside treatment, miR-1343-3p overexpression, and SLC25A1 silencing could all cause the accumulation of mitochondrial citrate, reduced mitochondrial membrane potential, increased ROS production, and decreased the levels of NADH, ATP, acetyl-CoA, free fatty acids, cholesterol, and triglycerides, while significantly inhibiting GC cell proliferation. However, after knocking down miR-1343-3p, the opposite results were observed, which were efficiently rescued by salidroside. In vivo, both salidroside treatment and the miR-1343-3p agomir administration significantly reduced tumor volume and weight. Tumor tissues from these groups showed increased miR-1343-3p expression, decreased SLC25A1 expression, and lipid metabolic changes consistent with those observed in vitro. Salidroside inhibits GC cell proliferation and tumor growth by upregulating the tumor-suppressive miR-1343-3p, which directly targets and downregulates the mitochondrial citrate transporter SLC25A1. Meanwhile, decreased mitochondrial citrate export, impaired mitochondrial function, and reduced lipid abundance are observed. These findings indicate that miR-1343-3p and SLC25A1 may be promising therapeutic targets for metabolic intervention in gastric cancer.

PMID 43053216
阅读全文 →
PubMedClinical epidemiology2026-11-18

Fertility Treatment with Ovulation Induction or Intrauterine Insemination and the Risk of Cerebral Palsy in Offspring.

Kettner Laura Ozer LO, Henriksen Tine Brink TB, Kesmodel Ulrik Schiøler US, Rackauskaite Gija G et al.

To investigate the association between ovulation induction or intrauterine insemination and cerebral palsy in offspring, and to examine the potential mechanisms underlying an association, including specific treatment regimens, mediation by preterm birth, confounding by indication, and the association with specific subtypes of cerebral palsy. This nationwide cohort study included all liveborn, singleton children in Denmark conceived from July 1995 and born before January 2017. The children were followed until March 2022. Children conceived after ovulation induction or intrauterine insemination were identified from redeemed prescriptions for the specific hormones used for these treatments, recorded in the Danish National Prescription Registry. Children with cerebral palsy were identified from the Danish Cerebral Palsy Registry and the Danish Cerebral Palsy Follow-up Program. The study included 1,231,058 singleton children; 47,017 children were conceived after ovulation induction or intrauterine insemination, and 2,104 children were diagnosed with cerebral palsy. Children conceived after ovulation induction or intrauterine insemination had an increased risk of cerebral palsy compared to spontaneously conceived children (adjusted odds ratio (aOR): 1.36; 95% confidence interval (CI): 1.11-1.66). The point estimate remained similar in a sibling analysis. The risk was primarily related to the use of clomiphene citrate (aOR: 1.44; 95% CI: 1.16-1.80). A mediation analysis showed that most of the increased risk was statistically mediated by prematurity and antecedent factors (proportion eliminated: 87%; 95% CI: 36-137%). In line with this, the risk was highest for spastic bilateral cerebral palsy (aOR: 1.76; 95% CI: 1.33-2.34), severe motor impairment (aOR: 1.66; 95% CI: 1.17-2.35), and for cerebral white matter lesions (aOR: 1.70; 95% CI: 1.24-2.33). Ovulation induction or intrauterine insemination was associated with an increased risk of cerebral palsy in offspring. The risk was related to treatment with clomiphene citrate, and most of the increased risk was statistically mediated by prematurity and antecedent factors.

PMID 43048637
阅读全文 →
PubMedCompendium of continuing education in dentistry (Jamesburg, N.J. : 1995)2026-11-18

Stannous Fluoride Deposition Into Plaque Biofilm: Effects of Formulation Chemistry and Hops β-Acids Extract Dispersion.

St John Samuel S, Strand Ross R

To evaluate how surfactant-mediated biofilm disruption by hops beta (β)-acids extract influences stannous fluoride (SnF2) penetration and interaction with extracellular metabolites, including lipopolysaccharide (LPS). In two studies, oral biofilms were formed in vivo on artificial enamel surfaces mounted in dental appliances worn by volunteers and subsequently treated ex vivo under controlled conditions. Across the studies, biofilms were treated with supernatants of various commercial 0.454% SnF2 dentifrices containing: (1) pyrophosphate; (2) potassium nitrate (KNO3) and pyrophosphate; (3) tripolyphosphate; and (4) gluconate/citrate-stabilized 0.454% SnF2 (Crest) with and without hops β-acids extract (Activ Bio-Cleanser™). Both studies used phosphate-buffered saline as a negative control (NC). Confocal laser scanning microscopy with component-specific fluorescent probes was used to quantify Sn and LPS distribution relative to bacterial biomass, biofilm thickness, and extracellular polymeric substance (EPS) structure. Image analysis was used to quantify Sn and LPS signal within bacterial regions, normalized to bacterial volume or area; statistical comparisons were made across conditions. SnF2 uptake and penetration varied significantly across formulations. In study 1, the rank order from greatest to least for Sn deposition and LPS neutralization was: gluconate/citrate > KNO3 + pyro > pyro > NC (P < 0.05 between groups). In study 2, the rank order from greatest to least was: gluconate/citrate + hops > gluconate/citrate > tripolyphosphate and KNO3 + pyro > NC (P < 0.05 between groups). Some stabilized SnF2 systems exhibited limited penetration, consistent with diffusion barriers imposed by dense EPS matrices or over-stabilization reducing bioavailability. Gluconate/ citrate-stabilized SnF2-only treated biofilms showed higher deposition per unit bacteria than other SnF2 technologies but uniformly exhibited the majority of uptake in surface regions. In the formulation containing both hops and SnF2, increased Sn penetration and reduced detectable biofilm-associated LPS was observed, consistent with enhanced access of SnF2 to extracellular plaque components following surfactant-enabled biofilm modification. In this case, Sn penetration achieved high relative deposition per unit bacteria in the treated regions throughout the biofilm. Hops β-acids extract acts as a co-surfactant in toothpaste, capable of modifying EPS structure to improve accessibility and interaction of SnF2 with extracellular metabolites within oral biofilms. The observed changes in Sn penetration and biofilm-associated, extracellular LPS are consistent with enhanced cleaning with reduced concentration of known tissue irritants. These findings provide a mechanistic rationale for formulation strategies that enhance SnF2 accessibility within adherent oral biofilms through surfactant-based modification of EPS supporting more efficient biofilm management during oral hygiene and providing a basis for selecting toothpastes based on their efficacy.

PMID 43051125
阅读全文 →
PubMedAnalytical chemistry2026-11-18

Weakly Ionized Interface Breaks the Poly(A) Terminal Length Constraint in Freezing Directed Spherical Nucleic Acids.

Li Guangping G, Wu Xinyue X, Wang Cheng C, Gao Heng H et al.

Non-thiolated spherical nucleic acids (SNAs) are widely used in biochemical applications, yet their synthesis remains constrained by sequence-dependent DNA adsorption onto gold nanoparticles (AuNPs). In freezing method, efficient adsorption typically requires a long poly(A) (≥10 nt), although the origin of this requirement remains unclear. Here, we show that this limitation arises primarily from the highly charged interface of citrate-stabilized AuNPs rather than the freezing process itself. Replacing citrate with weakly ionized ascorbic acid reduces interfacial electrostatic repulsion and promotes DNA adsorption, enabling stable SNAs with terminal fragments containing only two adenines (≥2 nt) and breaking the Poly(A) length limitation in freezing directed spherical nucleic acids. In this system, adenine accessibility, rather than sequence position or distal composition, governs adsorption behavior. Benefiting from the weakly ionized interfacial interactions, the resulting SNAs exhibit a high DNA packing density, imparting excellent colloidal stability (stable for 50 days in 0.1 M NaCl) and reproducible plasmonic properties (RSD = 5.1%). These findings establish interfacial interaction engineering as a general strategy for sequence-independent construction of non-thiolated SNAs.

PMID 43046419
阅读全文 →
PubMedEuropean journal of endocrinology2026-11-18

Hypogonadism in men with prolactinoma.

Broul Marek M, Hujová Aneta A, Radovnická Lucie L, Malucelli Alberto A et al.

Hypogonadism is one of the most consequential manifestations of prolactinoma in men, yet its course is often reduced to a single testosterone result. Prolactin excess can reversibly suppress hypothalamic-pituitary-gonadal signalling, whereas large tumours may damage gonadotroph function and other pituitary axes. These mechanisms create a dynamic phenotype that includes androgen-deficiency symptoms, impaired spermatogenesis, anaemia, adverse body composition, skeletal fragility and sexual dysfunction. Dopamine agonists are the usual first causal treatment, and transsphenoidal surgery is appropriate in selected patients; neither biochemical control nor tumour shrinkage proves gonadal or sexual recovery. Contemporary cohorts indicate that testosterone recovery occurs mainly during the first year but may continue through 24 months, and is more likely with smaller tumours, higher baseline or six-month testosterone, earlier prolactin normalisation and preserved pituitary function. Men with persistent symptomatic hypogonadism require a fertility-sensitive decision: continued observation when recovery remains plausible, consideration of testosterone replacement when fertility is not sought, or specialist gonadotrophin treatment when fertility is desired; clomiphene is an off-label option supported only by small uncontrolled studies. Sexual desire and erectile function should be measured separately because both may remain impaired despite eugonadism and require additional cardiometabolic, medication and psychosexual assessment. This Review integrates endocrine, reproductive and sexual outcomes into a time-resolved framework. The central principle is that prolactin control, endogenous gonadal recovery, fertility and sexual recovery are related but non-equivalent treatment goals.

PMID 43046285
阅读全文 →
PubMedClinical nephrology. Case studies2026-11-18

Hypercalcemia in infantile primary distal renal tubular acidosis: Clinical manifestations, genetic mutations, and therapeutic approaches - A report of three case studies.

Jin Yanyan Y, Lin Qian Q, Sheng Aiqin A, Zhu Jianhong J et al.

This retrospective investigation analyzed three instances of infantile primary distal renal tubular acidosis (dRTA) accompanied by hypercalcemia, aiming to enhance comprehension of its clinical and molecular attributes, as well as diagnostic and therapeutic methodologies. The prevalent symptoms identified were vomiting and growth retardation, followed by hyperchloremic acidosis, alkaline urine (pH > 6.5), hypercalcemia, and nephrocalcinosis. Genetic examination uncovered one instance of homozygous SLC4A1 mutation and two instances of compound heterozygous ATP6V0A4 mutations. Acidosis was resolved through potassium citrate therapy, and serum calcium levels were promptly normalized. Throughout a follow-up period spanning 5 - 19 months, all infants exhibited significant catch-up growth. The study suggests that this condition is clinically subtle and that genetic examination expedites early diagnosis. Early alkali therapy reverses metabolic disorders and growth impairment; however, the pathogenesis and long-term prognosis necessitate further inquiry.

PMID 43048006
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多clomiphene citrate